Skip to main content

Table 2 Relationships between miR-29b expression and clinicopathological features of CRC patients

From: Overexpression of microRNA-29b inhibits epithelial-mesenchymal transition and angiogenesis of colorectal cancer through the ETV4/ERK/EGFR axis

Clinicopathological feature Case miR-29b expression p EVT4 expression p
Age (years)      
 < 60 35 0.56 ± 0.15 0.476 2.40 ± 0.31 0.493
 ≥ 60 41 0.54 ± 0.09 2.44 ± 0.19
Gender      
 Male 54 0.55 ± 0.12 0.999 2.42 ± 0.26 0.877
 Female 22 0.55 ± 0.11 2.43 ± 0.24
Tumor location      
Colon 29 0.57 ± 0.10 0.310 2.39 ± 0.22 0.404
 Rectum 47 0.54 ± 0.13 2.44 ± 0.27
Tumor size (cm)      
 < 5 41 0.53 ± 0.09 0.137 2.45 ± 0.20 0.302
 ≥ 5 35 0.57 ± 0.14 2.39 ± 0.30
Differentiation grade      
 Well/moderate 49 0.62 ± 0.09 < 0.001 2.28 ± 0.17 < 0.001
 Poor 27 0.42 ± 0.05 2.68 ± 0.12
LNM      
 No 40 0.65 ± 0.07 < 0.001 2.23 ± 0.16 < 0.001
 Yes 36 0.44 ± 0.06 2.63 ± 0.13
TNM staging      
 I/II 33 0.67 ± 0.06 < 0.001 2.19 ± 0.14 < 0.001
 III/IV 43 0.46 ± 0.07 2.60 ± 0.14
  1. CRC, colorectal cancer; miR-29b, microRNA-29b; ETV4, ETS variant 4; LNM, lymph node metastasis; TNM, tumor node metastasis